"By bringing together two experts in the ADC value chain, biopharmaceutical companies should benefit from shorter timelines and less complexity, allowing them to focus their efforts on drug discovery, ...
Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments. Many of those projects have centered on later stages of the production ...
Drug Substance manufacturing is a critical component of pharmaceutical production, requiring precise processes, rigorous quality control, and innovative solutions to overcome various challenges. From ...
Global High Potency API CDMOs Market OverviewThe global high potency active pharmaceutical ingredient (HPAPI) CDMOs market is ...
Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, ...
Eli Lilly has revealed the location of the first of four large-scale manufacturing facilities that it plans to build in the U.S. The company has selected Goochland County, Virginia, as the site of a ...
While the United Kingdom feted President Trump in his second state visit, GSK said Wednesday it will spend $30 billion over the next five years to build new manufacturing and research facilities ...
Scheduled for August 2025 completion, the initial $2-billion phase included construction of a 1-million-sq-ft complex with two drug substance manufacturing buildings, each containing four 20,000-liter ...
QINGDAO, CHINA, January 19, 2026 /EINPresswire.com/ — As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened ...
Emergent’s Canton facility will manufacture drug substance and obtains exclusive distribution rights GAITHERSBURG, Md. and GENEVA, April 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: ...
India hosts more active pharmaceutical ingredient (API) manufacturing sites that are compliant with the U.S. Food and Drug Administration than any country outside the U.S., and it produces more ...